Form 4: Ultragenyx EVP Karah Parschauer Reports Stock Transactions

EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., Karah Parschauer, reports stock sales and acquisitions, including restricted stock units and stock options.

Summary

• Karah Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., filed a Form 4 detailing changes in beneficial ownership.
• On February 27, 2025, Parschauer sold 2,230 shares of common stock at $42.93 per share and 760 shares at $42.75 per share.
• On March 1, 2025, Parschauer acquired 14,494 shares of common stock through the award of Restricted Stock Units (RSUs) under the company's 2023 Incentive Plan.
• Also on March 1, 2025, Parschauer acquired a stock option for 26,074 shares with an exercise price of $42.92.
• Following these transactions, Parschauer beneficially owns 69,690 shares of common stock and stock options for 26,074 shares.
• The RSUs vest in equal installments over four years, and the stock options vest over four years with a combination of annual and monthly vesting.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and stock sales. There's no indication of unusual activity or significant concerns.

Positives

• The grant of RSUs and stock options to Parschauer aligns her interests with the long-term success of the company.

Future Outlook

The vesting schedules of the RSUs and stock options suggest a multi-year commitment by the executive.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their trading activities. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the pharmaceutical industry, used to incentivize executives and align their interests with shareholders.
• Vesting schedules of four years are typical for such grants, ensuring long-term commitment.
• Comparing the size of the grants to those of executives at similar-sized biotech companies (e.g., BioMarin, Sarepta) would provide further context.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting equity.
• The vesting schedules incentivize the executive to remain with the company, benefiting employees and other stakeholders.

Key Dates